6 December 2013 - In final draft guidance the NICE has recommend the use of Genzyme's drug for multiple sclerosis Aubagio (teriflunomide). NICE is appraising teriflunomide as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS). This is a chronic, disabling, neurological condition that, as it progresses, can be life altering and has a substantial negative impact on quality of life and activities of daily living. According to the draft guidance, teriflunomide is recommended for treating adults with active RRMS (normally defined as 2 clinically significant relapses in the previous 2 years), only if:

• they do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and
• the manufacturer provides teriflunomide with the discount agreed in the patient access scheme.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICERecommendsNewTreatmentOptionMultipleSclerosis.jsp